Mizuho Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Vamil Divan maintains a Neutral rating on Revance Therapeutics (NASDAQ:RVNC) and lowers the price target from $9 to $8.

May 10, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mizuho analyst Vamil Divan maintains a Neutral rating on Revance Therapeutics and lowers the price target from $9 to $8, indicating a cautious outlook on the stock's short-term price movement.
The adjustment of the price target by a reputable analyst can influence investor sentiment and stock price. However, maintaining a Neutral rating suggests that the analyst sees limited upside or downside potential in the near term, which might lead to a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100